Who Paid My Doc
Adam Brufsky
Pittsburgh, PA Medical Doctor
NPI 1518939537 CMS profile 23688
300 Halket St, Suite 4628, Pittsburgh, PA 15213
General payments
$1,306,008
Research payments
$132,881
Ownership & investment interest
$0
Research they led as principal investigator
$4,731,048
Through program year 2025, Adam Brufsky of Pittsburgh, PA is reported in the CMS Open Payments database as having received $1,306,008 across 940 general payments and $132,881 in research payments paid to them. Separately, studies naming them as principal investigator received $4,731,048 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
14 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $226,670 | 139 | |
| 2025 | Research | $22,629 | 17 | |
| 2024 | General | $328,724 | 226 | |
| 2024 | Research | $18,223 | 10 | |
| 2023 | General | $315,035 | 217 | |
| 2023 | Research | $17,618 | 14 | |
| 2022 | General | $120,427 | 82 | |
| 2022 | Research | $18,110 | 11 | |
| 2021 | General | $98,848 | 69 | |
| 2021 | Research | $18,823 | 15 | |
| 2020 | General | $105,073 | 65 | |
| 2020 | Research | $23,429 | 19 | |
| 2019 | General | $111,231 | 142 | |
| 2019 | Research | $14,051 | 2 |
Beside peers
- Adam Brufsky
- Pennsylvania median
- Middle half of Pennsylvania
- National median
In program year 2025, general payments to Adam Brufsky were reported at $226,670. Among 44,217 Pennsylvania profiles paid that year, the median was $168 and the middle half received between $50 and $597.
Show as a table
| Year | Adam Brufsky | Pennsylvania median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $111,231 | $156 | $46–$628 | $163 |
| 2020 | $105,073 | $109 | $33–$381 | $114 |
| 2021 | $98,848 | $125 | $35–$469 | $132 |
| 2022 | $120,427 | $136 | $40–$499 | $149 |
| 2023 | $315,035 | $147 | $46–$523 | $160 |
| 2024 | $328,724 | $156 | $46–$568 | $164 |
| 2025 | $226,670 | $168 | $50–$597 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
1,035
Drug cost
$1,614,923
Branded share of claims
12.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ibrance Palbociclib | Brand | 59 | $1,002,122 | |
| Orserdu Elacestrant Hcl | Brand | 16 | $370,714 | |
| Verzenio Abemaciclib | Brand | 21 | $221,796 | |
| Anastrozole | Generic | 394 | $7,415 | |
| Exemestane | Generic | 62 | $4,441 | |
| Letrozole | Generic | 184 | $4,036 | |
| Tamoxifen Citrate | Generic | 97 | $2,425 | |
| Ibandronate Sodium | Generic | 11 | $620 | |
| Oxybutynin Chloride Er Oxybutynin Chloride | Brand | 13 | $280 | |
| Prochlorperazine Maleate | Generic | 45 | $245 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 9 billing codesPaid by Medicare
$26,944
Medicare patients
190
Services billed
395
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Cancer | 75% | |
| High blood pressure | 59% | |
| Arthritis | 50% | |
| Osteoporosis | 36% | |
| Depression | 19% | |
| Diabetes | 16% | |
| Ischemic heart disease | 15% | |
| Chronic kidney disease | 11% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 11 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Trodelvy |
|
$104,159 | — | — |
| IBRANCE |
|
$61,529 | 59 | — |
| VERZENIO |
|
$6,650 | 21 | — |
| Orserdu |
|
$6,090 | 16 | — |
| NERLYNX |
|
$4,797 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 11 in the dashboard with a free accountRecords
1,028 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.